Gal Cohen, B.Sc, MBA.

Chairman and Chief Executive Officer

Gal Cohen serves as the chairman and CEO of Quark Pharmaceuticals Inc., and in addition as executive chairman of Ayana pharma Ltd.

Prior to joining Quark, Gal served for over 12 years as CEO of MediWound (Nasdaq: MDWD), a fully integrated biopharmaceutical company, where he raised over $300M from private, strategic, governmental and public sources.

After taking the company public, Gal continued to lead the company directing its financial, legal and IR teams, gaining coverage by 6 prominent Wall Street analysts. Under his leadership, the R&D team successfully completed the development of an innovative biological drug, including CMC, non-clinical and two phase 3 clinical studies that resulted in obtainment of a centralized procedure marketing authorization for the drug in EU, BLA under review by FDA and marketing approvals in additional international markets. Under his management, the company operated a sterile manufacturing facility to produce both API and sterile drug products, passing authorities’ cGMP inspections and supplying a sterile, cold chain product, through an established global supply chain. Gal has formed the company’s commercial arm operating across the EU which then launched NexoBrid® and secured national reimbursements. Leading business development efforts, he signed distribution agreements in the U.S., Asia Pacific, Latin America, and CIS regions.

Prior to joining MediWound, Gal held several management positions at Teva including Director of Strategic Business Planning & New Ventures (enriching Teva’s pipeline through various business structures as well as analyzing new strategic pharmaceutical areas of interest) and Projects Manager – Global Products Division (globally launched Copaxone® and developed and launched various medical devices).

Gal holds a B.Sc. in Industrial Engineering and Management (cum laude) from Technion – Israel Institute of Technology and an M.B.A. (cum laude) from Tel Aviv University.

Tomer Natan, LLM, BB, CPA

Chief Financial Officer

Mr. Natan has over 15 years of financial experience. He joined Quark Pharmaceuticals in 2005 as Senior Director of Finance & Operations for Quark, and has been serving as the company’s CFO since 2011. Prior to joining Quark, Mr. Natan had served as Senior Auditor at Ernst & Young Israel. Mr. Natan received his Master of Law degree from Bar-Ilan University. He holds a Bachelor of Business degree with a major in accounting from the College of Management, and he is a Certified Public Accountant in Israel.

Elena Feinstein, MD, Ph.D.

Chief Scientific Officer

Elena Feinstein, MD, PhD., CSO. Dr. Feinstein joined Quark in 1998, and since has held increasingly senior positions, including Director of Research and Development, Vice President of Research and Vice President of Technology Development. Prior to joining Quark, Dr Feinstein worked for 12 years in the Weizmann Institute of Science as Doctoral Fellow, Post-Doctoral Fellow, Scientist and Senior Staff Scientist. She has a 2-year practical clinical experience from Clinical Pediatric Hospital No.1 in Moscow, Russia. Dr. Feinstein obtained her M.D. degree from the 2nd Moscow Medical Institute (Moscow Medical University) and completed her Ph.D. studies (Bondi Prize for Excellence) in the Department of Chemical Immunology, the Weizmann Institute of Science, Rehovot, Israel. Dr. Feinstein has been a leading or senior author of numerous publications in peer-reviewed journals and is named as an inventor on numerous patents.

Daniel P. Cafaro

Chief Regulatory Officer and President, US Operations

Daniel P. Cafaro joined Quark in 2017 to lead regulatory activities for the company.  Mr. Cafaro is responsible for regulatory affairs, quality,  pharmaceutical development, biostatistics and data management.  He also serves as the site head of Quark’s US operations.  Mr. Cafaro brings over 30 years of experience in managing worldwide regulatory and development programs in the pharmaceutical and biotechnology industries.  Prior to Quark, he was Vice President of Regulatory Affairs and Compliance at XOMA, a biotech company in the Bay Area serving in multiple regulatory and clinical capacities as a member of the senior management team for more than 15 years. He held leadership roles of several development programs including ophthalmology and joint development collaborations. Prior to XOMA, Mr. Cafaro spent 15 years at Allergan, Inc., managing worldwide regulatory affairs and product development. He belongs to several professional societies including the Regulatory Affairs Professional Society (RAPS), The Organisation for Professionals in Regulatory Affairs (TOPRA), and the Drug Information Association (DIA). Mr. Cafaro holds a B.S. in Chemistry from the University of California Los Angeles.

Nitsan Halevy, MD

Chief Development Officer

Dr. Halevy is a senior medical officer heading clinical development at Quark Pharmaceuticals and is responsible for clinical development, clinical operations, pharmacovigilance, and project management. Dr. Halevy joined Quark in 2018 and has previously served as VP Medical Innovation. Prior to joining Quark, Dr. Halevy had worked as Clinical Program Lead in Teva’s Innovative R&D organization, focusing on Multiple Sclerosis. Earlier in her career, she held roles of increasing responsibility and scope in clinical development and medical affairs at Novartis, focusing on Neurology and Ophthalmology. Dr. Halevy gained experience leading all aspects of clinical trials in the Department of Preventive Medicine at Brigham and Women’s Hospital in Boston. Dr. Halevy holds an M.D. from the Joyce and Irving Goldman Medical School at Ben-Gurion University in Be’er Sheva and completed her internship at Sapir Medical Center in Kfar Saba.

Juliana Friedmann, M.Sc.

Senior Vice President of Strategy and Planning

Ms. Friedmann joined Quark in 1998. Throughout her career spanning over 20 years, Ms. Friedmann’s experience has focused on intellectual property, marketing, business development, and strategic planning activities in the chemical and pharmaceutical industries. In 1983, Ms. Friedmann joined Dead Sea Bromine, a subsidiary of Israel Chemicals Ltd. (ICL), the largest chemical group in Israel. Since then and until joining Quark, Ms. Friedmann held a number of progressively senior positions, including managing fine organic chemical products for life science industries, heading a major biocide joint venture with a U.S. industry leader, and directing business development and new product development activities. Previously Ms. Friedmann worked as a Patent Attorney in Milan, Italy, at one of Italy’s largest patent firms. Ms. Friedmann received her B.Sc. and M.Sc. degrees in Chemical Engineering from Ben Gurion University, Israel.

Hagit Asush, PhD

Vice President, Research Operation

Dr. Ashush Hagit joined Quark Pharmaceuticals in 2001 and has been serving as Quark’s Vice president of Research Operation since 2009. In her role at Quark, she is responsible for numerous research programs, advancing them from concept to drug nomination and initiation of IND-enabling studies. Previously, Dr. Ashush held senior positions in the research department with increasing responsibilities, expanding Quark’s drug discovery platform and playing an integral role in the advancement of siRNA oligonucleotides as therapeutic agents for kidney, cancer and skin disorders.

Dr. Ashush holds an M.Sc (summa cum laude) and PhD (summa cum laude) in Biology from the Institute for Cancer Research, Bar-Ilan University, Ramat-Gan, Israel

Teddy Ercegovic, PhD

Senior Vice President, Intellectual Property

Dr. Teddy Ercegovic joined Quark in 2014 to head its IP department. Before joining Quark, Dr. Ercegovic gained more than 25 years of experience in the IP field. He has worked as Examiner at the Swedish Patent Office, followed by five years in private practice as patent attorney in one of Sweden’s leading law firms. From 2002 to 2014 Dr. Ercegovic  developed and lead the patent department of Ferring Pharmaceuticals, gaining further experience in multi-jurisdictional patent litigation, pharmaceutical product Life Cycle Management and business development. Dr. Ercegovic received a Ph.D. degree in Organic Chemistry from Lund University, Sweden.

Dan Odenheimer, PhD

Senior Vice President, Bio-Statistics and Clinical Data Management

Daniel J. Odenheimer PhD joined Quark in 2014 as Vice President, Biostatistics and was promoted to Senior Vice President, Biostatistics in September 2017.  In January 2019, Dr. Odenheimer was also made responsible for the Data Management group.  Prior to joining Quark, Dr. Odenheimer served as Vice President of Clinical Development and Evaluation at Human Genome Sciences where he led the Biostatistics and Drug Safety functions, and also directed Phase I-III development for drugs in the General Medicine portfolio.  From 1989 to 1997, Dr. Odenheimer was Director, Clinical Research at Boehringer Mannheim Pharmaceuticals, where he was clinical director for the thrombolytic drug development program.  Prior to joining Boehringer Mannheim, Dr. Odenheimer worked as a statistician and clinical scientist in the cardiovascular group at Warner Lambert/Parke Davis.  He holds a BA in Human Genetics from the University of California, Berkeley, an MS in Biostatistics from the University of Michigan, and a PhD in Epidemiology from the University of Michigan.